Spelling suggestions: "subject:"antitubercular agents"" "subject:"antituberculars agents""
1 |
The Pharmacokinetics of some anti-tuberculous drugs.January 1991 (has links)
by Walubo Andrew. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1991. / Bibliography: leaves 148-174. / ABSTRACT --- p.i / declaration --- p.iv / acknowledgements --- p.v / Chapter chapter 1 --- general introduction --- p.1 / Chapter chapter 2 --- literature review --- p.5 / Chapter section 1 --- isoniazid --- p.5 / Chapter section 2 --- rifampicin --- p.19 / Chapter section 3 --- pyrazinamide --- p.27 / Chapter section 4 --- an overview of the use of antituberculous drugs in uganda and hong kong --- p.30 / Chapter section 5 --- review of analytical methods --- p.40 / Chapter section 6 --- conclusions from the reviews --- p.44 / Chapter chapter 3 --- some principles of pharmacokinetics --- p.47 / Chapter section 1 --- introduction --- p.47 / Chapter section 2 --- application of pharmacokinetics --- p.55 / Chapter chapter 4. --- aims of the present project --- p.66 / Chapter chapter 5 --- chromatographic methods --- p.68 / Chapter section 1 --- a simultaneous assay for isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid in the rabbit --- p.68 / Chapter section 2 --- a simultaneous assay for rifampicin and pyrazinamide in human plasma --- p.89 / Chapter chapter 6 --- the pharmacokinetics of isoniazid and hydrazine metabolite in the plasma and cerebrospinal fluid of rabbits --- p.91 / Chapter chapter 7 --- the disposition of anti-tuberculous drugs in the plasma of elderly patients --- p.108 / Chapter SECTION 1 --- METHODS --- p.109 / Chapter SECTION 2 --- CLINICAL ASSESSMENT --- p.112 / Chapter SECTION 3 --- GENERAL FINDINGS. --- p.117 / Chapter 1)- --- THE DISPOSITION OF ISONIAZID AND HYDRAZINE METABOLITE IN THE PLASMA OF ELDERLY PATIENTS --- p.117 / Chapter 2) - --- "THE DISPOSITION OF ISONIAZID, PYRAZINAMIDE AND RIFAMPICIN IN THE PLASMA OF ELDERLY PATIENTS" --- p.129 / Chapter SECTION 4 --- CASE REPORT --- p.139 / Chapter CHAPTER 8 --- p.145 / Chapter SECTION 1 --- GENERAL CONCLUSIONS --- p.145 / Chapter SECTION 2 --- FUTURE STUDIES --- p.147 / REFERENCES --- p.148 / APPENDICES: --- p.AO / Chapter APPENDIX A --- (WORK SHEETS) --- p.AO / Chapter APPENDIX B --- (SCIENTIFIC COMMUNICATIONS) --- p.BO
|
2 |
Studies on the biosynthesis of capreomycinWang, Mu, 1964- 17 June 1993 (has links)
Graduation date: 1994
|
3 |
A study of the antituberculous and pharmacological action of some substituted pyridine and piperidine compoundsChin, Lincoln, 1924- January 1954 (has links)
No description available.
|
4 |
Research on the post-PKS modification steps of rifamycin B biosynthesis in Amycolatopsis mediterranei S699 /Xu, Jun, January 2005 (has links)
Thesis (Ph. D.)-- University of Washington, 2005. / Vita. Includes bibliographical references (leaves 145-163).
|
5 |
The role of iron in the host-parasite relationship in experimental airborne tuberculosisHank, Jacquelyn A., January 1976 (has links)
Thesis--Wisconsin. / Includes bibliographical references (leaves 30-32).
|
6 |
Antitubercular compoundsTSAO, Shung Ling 01 June 1949 (has links)
No description available.
|
7 |
The pharmaceutical development of a fixed combination anti-tuberculosis dosage formEbrahim, Salima January 1998 (has links)
A research report submitted to the Faculty of Health Sciences, University of the
Witwatersrand In partial fulfilment of the requirements for the degree of Master of
Science in medicine (Pharmaceutical affairs)
Johannesburg, 1998 / Despite the availability of highly effective treatment regimens for tuberculosis, cure rates
remain low for tuberculosis mainly due to patient non-compliance which results in the
occurrence of multi drug resistance tuberculosis. To avoid the problem of further creation
and propagation of multi drug-resistant tuberculosis, patients should be given fixed-dose
combinations of anti-tubercular drugs whenever self-administration of drugs iJ permitted.
During this study, an anti-tuberculosis extemporaneous powder for suspension was
optimized in order to formulate a fixed combination of rifampicin. isoniazid, pyrazinamide
and ethambutol hydrochloride as a powder to be ' . constituted with water by the patient prior
to administration. Once an effective manufacturing method was established, different
suspending agents were evaluated by their influence on powder flow properties and
sedimentation volume on the powder blends. Sodium starch glycollate was chosen as the
suspending agent of choice because as the concentration of sodium starch glycollate was
increased, the powder flow properties of the powder blends improved. The sedimentation
volume also. increased with the increasing concentration of sodium starch glycollate in the
powder blends. A suitable flavour and colour was also determined to increase the
acceptability of the preparation to the patient. Liquorice flavour was the most acceptable in
terms of colour and flavour. An evaluation of the dissolution characteristics of the
extemporaneous powder for suspension was also conducted in comparison to the dissolution
profiles from commercially available tablet dosage forms. The dissolution rates from the
powder tor suspension for rifampicin, isoniazid and pyrazinamide was faster than from the
commercially available tablet dosage form, while the dissolution race of ethambutol HCl
from the powder closely resembles the dissolution profile from the Rolab-Ethambutol HCIR
tablet dosage form
Therefore. a fixed combination powder for suspension was achieved and with its ease of
administration would increase the compliance amongst tuberculosis patients. and increase
therapeutic outcomes. / MT2017
|
8 |
Acute exposure to ethionamide in an Fmo 1/2/4 null murine modelPalmer, Amy L. (Amy Leigh) 22 March 2012 (has links)
The use of ethionamide has been increasing in drug regiments due to greater incidence of multidrug resistance tuberculosis around the world. Ethionamide is metabolized into antimicrobial relevant compounds by different flavin-containing monooxygenase (FMO) enzymes including FMO1, FMO2, and FMO3. FMOs are found in various locations in the body including the intestine, kidney, liver, and lung. In humans, active functional FMO2*1 is found in approximately 50% of Sub-Saharan Africans and a truncated, inactive FMO2*2, is found in all Caucasians and Asians. Polymorphisms in human FMO2 were investigated by comparing differences in metabolism of ethionamide in wildtype mice relative to Fmo 1/2/4 null mice. All mice were capable of metabolizing ethionamide into ethionamide S-oxide and 2-ethyl-4-amidopyridine. Wildtype mice had higher plasma levels of metabolites than parent compound. In contrast, Fmo 1/2/4 null mice had higher plasma levels of parent compound than metabolites. In both mouse populations, maximum ethionamide concentration peaked at 2 hours post-exposure. Increased metabolism of ethionamide in wildtype mice may deplete glutathione pools and induce oxidative stress leading to greater toxicity and adverse drug effects. This murine model is used to demonstrate the polymorphic differences of FMO2 occurring in humans. Taking these differences into account, polymorphisms of drug metabolizing enzymes provide a basis for increasing specific and individualized drug treatment regiments in susceptible populations. / Graduation date: 2012
|
9 |
Pyridine Derivatives of NaphthoquinonePlatas, Oscar R. 08 1900 (has links)
This paper deals with the preparation of pyridinium derivatives of naphthoquinone. The starting material was 2,3-dichloro-1,4-naphthoquinone, and it was reacted with pyridine and 4-n-alkyl-pyridine derivatives.
|
10 |
Tuberculosis in elderly presentation and therapeutic problem: a clinical and pharmacological study.January 1994 (has links)
by Cheung Wah. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1994. / Includes bibliographical references (leaves 64-68). / Tuberculosis in the Elderly : Presentation and Therapeutic Problems -a Clinical and Pharmacological Study / Contents / Chapter 1. --- Summary --- p.6 / Chapter 2. --- Introduction --- p.7 / Chapter 3. --- Aims of the Study --- p.11 / Chapter 4. --- Subjects and Methods --- p.12 / Chapter 5. --- Results --- p.36 / Chapter 6. --- Discussion --- p.55 / Chapter 7. --- Conclusion --- p.61 / Chapter 8. --- Acknowledgement --- p.63 / Chapter 9. --- References --- p.64
|
Page generated in 0.0562 seconds